Alnylam Pharmaceuticals Inc., an RNA interference (RNAi) therapeutics company, and Sharp, part of UDG Healthcare, have announced an agreement for the packaging of Alnylam’s approved RNAi therapeutic in European markets.   In accordance with this agreement, Sharp Belgium’s Hamont-Achel site will be responsible for the packaging of all of Alnylam’s products across European countries.   “This is a historical milestone for Alnylam Benelux and constitutes our first significant international investmen...